Avalo Therapeutics Inc

Research Avalo Therapeutics Inc (AVTX) on Bullrun: market cap USD 1.01B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAVTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.01B
• Financial periodFY2025
• RevenueUSD 59.00K
• Revenue growth-86.6%
• Net income-USD 78.26M

Valuation Snapshot

latest market cap is USD 1.01B.

About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc.

Frequently asked questions

What is Avalo Therapeutics Inc's market cap?

Avalo Therapeutics Inc's market capitalization is USD 1.01B.

What does Avalo Therapeutics Inc do?

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.